Evidence map›Paper›PMID 37093754›Full record

ArticleACS applied bio materials2023

Synthesis and Characterization of Folic Acid-Functionalized DPLA-co-PEG Nanomicelles for the Targeted Delivery of Letrozole.

Neda Rostami, Mohammad Mahmoudi Gomari, Majid Abdouss, Alaa Moeinzadeh, Edris Choupani, Reza Davarnejad, Reza Heidari, Sidi A Bencherif

Open access · hybridAbstract read
In one paragraph

Article in ACS applied bio materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 21 citations in OpenAlex.

  1. HACS applied bio materials · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Neda RostamiDepartment of Chemistry, Amirkabir University of Technology, Tehran 1591634311, Iran.
Mohammad Mahmoudi GomariDepartment of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Majid AbdoussDepartment of Chemistry, Amirkabir University of Technology, Tehran 1591634311, Iran.ORCID 0000-0003-2305-7985
Alaa MoeinzadehDepartment of Tissue Engineering and Regenerative Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Edris ChoupaniDepartment of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran 1449614535, Iran.
Reza DavarnejadDepartment of Chemical Engineering, Faculty of Engineering, Arak University, Arak 3848177584, Iran.
Reza HeidariResearch Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran 1411718541, Iran.
Sidi A BencherifDepartment of Chemical Engineering, Northeastern University, Boston, Massachusetts 02115, United States.ORCID 0000-0002-7704-5608
Iran University of Medical Sciences · IRAmirkabir University of Technology · IRAja University of Medical Sciences · IRArak University · IRUniversité de Technologie de Compiègne · FR

Funding

Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapyR01EB027705 · NIBIB · NORTHEASTERN UNIVERSITY · PI HATFIELD, STEPHEN MATTHEW · 2021 to 2024
$1.9M
NIBIB NIH HHS R01 EB027705
6 · The paper itself

Abstract

An effective treatment for hormone-dependent breast cancer is chemotherapy using cytotoxic agents such as letrozole (LTZ). However, most anticancer drugs, including LTZ, are classified as class IV biopharmaceuticals, which are associated with low water solubility, poor bioavailability, and significant toxicity. As a result, developing a targeted delivery system for LTZ is critical for overcoming these challenges and limitations. Here, biodegradable LTZ-loaded nanocarriers were synthesized by solvent emulsification evaporation using nanomicelles prepared with dodecanol-polylactic acid-co-polyethylene glycol (DPLA-co-PEG). Furthermore, cancer cell-targeting folic acid (FA) was conjugated into the nanomicelles to achieve a more effective and safer cancer treatment. During our investigation, DPLA-co-PEG and DPLA-co-PEG-FA displayed a uniform and spherical morphology. The average diameters of DPLA-co-PEG and DPLA-co-PEG-FA nanomicelles were 86.5 and 241.3 nm, respectively. Our preliminary data suggest that both nanoformulations were cytocompatible, with ≥90% cell viability across all concentrations tested. In addition, the amphiphilic nature of the nanomicelles led to high drug loading and dispersion in water, resulting in the extended release of LTZ for up to 50 h. According to the Higuchi model, nanomicelles functionalized with FA have a greater potential for the controlled delivery of LTZ into target cells. This model was confirmed experimentally, as LTZ-containing DPLA-co-PEG-FA was significantly and specifically more cytotoxic (up to 90% cell death) toward MCF-7 cells, a hormone-dependent human breast cancer cell line, when compared to free LTZ and LTZ-containing DPLA-co-PEG. Furthermore, a half-maximal inhibitory concentration (IC50) of 87 ± 1 nM was achieved when MCF-7 cells were exposed to LTZ-containing DPLA-co-PEG-FA, whereas higher doses of 125 ± 2 and 100 ± 2 nM were required for free LTZ and LTZ-containing DPLA-co-PEG, respectively. Collectively, DPLA-co-PEG-FA represents a promising nanosized drug delivery system to target controllably the delivery of drugs such as chemotherapeutics.

Indexed as

Antineoplastic AgentsBreast NeoplasmsNanoparticlesDrug CarriersFemaleFolic AcidHormonesHumansLactatesLetrozolePolyethylene GlycolsWaterAntineoplastic AgentsDrug CarriersFolic AcidHormonesLactatesLetrozolePolyethylene Glycolspoly(lactic acid-ethylene glycol)Waterbreast cancerfolic acidletrozolenanomicellestargeted delivery

Identifiers

PMID37093754
PMCPMC10629236
OpenAlexW4366819983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.